Literature DB >> 2352012

Correlation of clinical and pathological features in surgically treated craniopharyngiomas.

T E Adamson1, O D Wiestler, P Kleihues, M G Yaşargil.   

Abstract

Surgical specimens of 104 craniopharyngiomas from 93 patients were reviewed and characterized histopathologically. They were found to have either a classic adamantinous or a squamous papillary structure. The clinical features of each group were then assessed. The frequently solid (50%), always uncalcified squamous papillary tumor type was found in one-third of the adult patients (greater than or equal to 20 years) but did not occur in children. It was associated with a good functional postoperative outcome (84.6%). There have been no cases of tumor recurrence in the squamous papillary group. However, in the group with the adamantinous type of craniopharyngioma, the recurrence rate was 13% in adult patients and 9% in children. When compared to the adult adamantinous cases, the incidence of visual deficits was lower in the squamous papillary group (75% vs. 84%) but the incidence of endocrine abnormalities was higher (75% vs. 52%). Thus, the preoperative, operative, and postoperative features of the two types of craniopharyngioma were found to be distinctly different in adults and children.

Entities:  

Mesh:

Year:  1990        PMID: 2352012     DOI: 10.3171/jns.1990.73.1.0012

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  39 in total

1.  Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations.

Authors:  Shigeki Sekine; Tatsuhiro Shibata; Akiko Kokubu; Yukio Morishita; Masayuki Noguchi; Yukihiro Nakanishi; Michiie Sakamoto; Setsuo Hirohashi
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 2.  Intracavitary therapeutic options in the management of cystic craniopharyngioma.

Authors:  Adrián Cáceres
Journal:  Childs Nerv Syst       Date:  2005-07-19       Impact factor: 1.475

Review 3.  Craniopharyngioma surgery.

Authors:  Jürgen Honegger; Marcos Tatagiba
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

4.  Pathological characteristics of surgically removed craniopharyngiomas: analysis of 131 cases.

Authors:  G T Szeifert; L Sipos; M Horváth; M H Sarker; O Major; B Salomváry; S Czirják; K Bálint; F Slowik; L Kolonics
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

5.  Craniopharyngioma extended into the posterior fossa.

Authors:  A C Sarioğlu; F Ozlen; M Hanci; B Oz
Journal:  Neurosurg Rev       Date:  1996       Impact factor: 3.042

6.  Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.

Authors:  Prit Benny Malgulwar; Aruna Nambirajan; Pankaj Pathak; Mohammed Faruq; Vaishali Suri; Chitra Sarkar; Amandeep Jagdevan; Bhawani Shankar Sharma; Mehar Chand Sharma
Journal:  J Neurooncol       Date:  2017-05-12       Impact factor: 4.130

7.  Long-term results of the surgical treatment of craniopharyngioma: the experience at the Policlinico Gemelli, Catholic University, Rome.

Authors:  M Caldarelli; L Massimi; G Tamburrini; M Cappa; C Di Rocco
Journal:  Childs Nerv Syst       Date:  2005-07-02       Impact factor: 1.475

8.  Monstrous craniopharyngioma. Case presentations and term proposal.

Authors:  Humberto Trejos; Adrian Caceres; Juan L Segura
Journal:  Childs Nerv Syst       Date:  2005-03-10       Impact factor: 1.475

9.  The cell-cycle kinetics of craniopharyngioma and its clinical significance.

Authors:  Jianguo Xu; Chao You; Liangxue Zhou; Qiang Li; Peizhi Zhou; Ni Chen
Journal:  J Neurooncol       Date:  2009-11-24       Impact factor: 4.130

10.  Correlation between clinical characteristics and proliferative activity in patients with craniopharyngioma.

Authors:  M Losa; A Vimercati; S Acerno; R L Barzaghi; P Mortini; F Mangili; M R Terreni; G Santambrogio; M Giovanelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.